Related Experiment Video

Updated: May 29, 2026

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

HER2-overexpressing breast cancer: time for the cure with less chemotherapy?

Sherene Loi1, Evandro de Azambuja, Lina Pugliano

  • 1Breast Cancer Translational Research Laboratory, Institut Jules Bordet, L'Université Libre de Bruxelles, Brussels, Belgium. sherene.loi@bordet.be

Current Opinion in Oncology
|September 16, 2011
PubMed
Abstract

Insights

Dual anti-HER2 therapies show improved outcomes for HER2-positive breast cancer, potentially reducing the need for intensive chemotherapy. Future trials should consider estrogen receptor status and immunotherapy.

Area of Science:

  • Oncology
  • Immunology
  • Genetics

Background:

  • HER2-positive breast cancer treatment has advanced with new understanding of trastuzumab response.
  • HER2-positive breast cancer is a distinct subtype with evolving therapeutic strategies.

Purpose of the Study:

  • To review recent developments in HER2-positive breast cancer treatment.
  • To reflect on how new findings may shape future clinical trials for this breast cancer subtype.

Main Methods:

  • Review of recent clinical trial data.
  • Analysis of mechanistic understanding of trastuzumab response.

Main Results:

  • Dual anti-HER2 agents demonstrated superior pathological complete response rates compared to trastuzumab alone in neoadjuvant settings.
  • HER2-positive disease exhibits biological differences based on estrogen receptor status.
  • Effective adaptive immune response appears necessary for long-lasting clinical remissions with anti-HER2 therapy.

Conclusions:

  • The current era offers exciting therapeutic advancements for HER2-positive breast cancer.
  • Intensive chemotherapy may be avoidable for some patients by optimizing combinations of signal inhibitors.
  • Future clinical trials should be stratified by estrogen receptor status and incorporate immunotherapeutic approaches.

More Related Videos

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery13:19

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

Analysis of Targeted Viral Protein Nanoparticles Delivered to HER2+ Tumors11:52

Analysis of Targeted Viral Protein Nanoparticles Delivered to HER2+ Tumors

Published on: June 18, 2013

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...